Clinical Trial Update: BIBW 2992 (Afatinib) in Head & Neck Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating afatinib (BIBW 2992) in head and neck squamous cell carcinoma has completed, with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Gilotrif (Afatinib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Head and Neck Neoplasms, Carcinoma, Squamous Cell | Phase 2 | Status: COMPLETED | Results posted: 2013-12-25